ArticleEmerging microbes & infections2021
The prevalence of CRF55_01B among HIV-1 strain and its connection with traffic development in China.
Article in Emerging microbes & infections, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed.
- Molecular footprints of a traveling epidemic: CRF01_AE-cluster 5 (01_C5) might spread across Northeast and South China via middle-aged MSM.Emerging microbes & infections · 2026Article
- Changes in RPV Resistance-Related Mutations Among Antiretroviral Therapy-Naïve HIV-1-Positive Individuals - China, 2004-2023.China CDC weekly · 2026Article
- Emergence of newly reported HIV-1 recombinants CRF120_0107 and CRF149_01B in Guangxi Zhuang Autonomous Region, China: Molecular evidence and public health challenges.Biosafety and health · 2026Article
- Identification of a novel second-generation HIV-1 circulating recombinant form, CRF182_0708, in Yunnan, China.BMC infectious diseases · 2026Article
- Molecular network characteristics and transmissible drug resistance of HIV-1 CRF55_01B in Yunnan Province.BMC infectious diseases · 2026Article
- Geographical and temporal trends of HIV-1 subtypes and drug resistance in China: a nationwide study over two decades (2003-2024).The Journal of general virology · 2026Article
- Molecular genetic characterization of a novel HIV-1 circulating recombinant form (CRF205_0107) among men who have sex with men in Hangzhou, China.Frontiers in microbiology · 2026Article
- Network Dynamics and Evolutionary Drivers of HIV Drug Resistance in Eastern China, from 2022 to 2024.Viruses · 2025Article
- Drug resistance and genetic transmission characteristics of HIV-1 CRF55_01B in people living with HIV/AIDS (PLWHA) in Henan Province, China.Retrovirology · 2025Article
- Characteristics of molecular epidemiology and transmitted drug resistance among newly diagnosed HIV-1 infections in Lishui, China from 2020 to 2023.Virology journal · 2025Article
- Unraveling HIV-1 transmission patterns through molecular surveillance in a hotspot in Yunnan Province, China.Scientific reports · 2025Article
- Article
- Genetic characterization of a novel HIV-1 circulating recombinant form (CRF162_cpx) involving CRF01_AE, CRF07_BC and subtype B in Guangdong, China.Virus genes · 2025Article
- The origin and transmission of HIV-1 CRF80_0107 among two major first-tier cities in China.BMC infectious diseases · 2025Article
- Prevalence and transmission of pretreatment drug resistance in people living with HIV-1 in Shanghai China, 2017-2021.Virulence · 2024Article
- National and Regional Molecular Epidemiology of HIV-1 - China, 2004-2023.China CDC weekly · 2024Article
- Multiple third-generation recombinants formed by CRF55_01B and CRF07_BC in newly diagnosed HIV-1 infected patients in Shenzhen city, China.Virology journal · 2024Article
- Molecular transmission network analysis of newly diagnosed HIV-1 infections in Nanjing from 2019 to 2021.BMC infectious diseases · 2024Article
- Evaluating the spatial accessibility and spatial layout optimization of HIV/AIDS healthcare services in Shandong Province, China.Scientific reports · 2024Article
- Identification of a novel HIV-1 third-generation circulating recombinant form (CRF126_0755) in Guangdong, China.Archives of virology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CRF55_01B is a relatively "young" HIV strain. At present, we do not know much about its transmission characteristics in China. So, to describe the transmission characteristics of CRF55_01B strain among provinces and HIV infected people, and to analyze the reasons for its rapid epidemic in China, a total of 1237 subjects infected with CRF55_01B from 31 provinces spanning a period of 12 years from 2007 to 2018 were enrolled in this study. By constructing a molecular network and Bayesian correlation analysis, we found that CRF55_01B increased exponentially from 2005 to 2009 after its origin in Shenzhen, and increased rapidly after 2010. CRF55_01B began to spread to other provinces in 2007. After 2010, the strain showed a trend of rapid spread and epidemic from Guangdong-Shenzhen to other provinces in China. Guangdong, Shenzhen, Hunan, Beijing, Guangxi, Hubei, Jiangxi, Guizhou, Hebei, Anhui, Shanghai, Shandong, Henan, and Yunnan were the key provinces of CRF55_01B transmission. CRF55_01B, although originating from men who sex with men (MSM), was transmitted among heterosexuals in 2010. Males in heterosexuals played a crucial role in the transmission and diffusion of this strain. We also revealed that CRF55_01B might spread rapidly along with the rapid development of the Beijing-Guangzhou and Beijing-Kowloon railways. This study suggests that if we detect the spread of MSMs in time through molecular monitoring in the early stage of the epidemic, it can help us control the epidemic early and prevent its spread, which is of great significance to China's national prevention and control of HIV-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.